ISHITA DRUGS & INDUSTRIES LTD.

Ishita Drugs & Industries Ltd has announced the closure of its trading window for designated persons. This closure will be effective from Wednesday, July 1, 2026, and will remain in effect for 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Ishita Pharmaceuticals, a related party of Ishita Drugs & Industries Ltd, has acquired 223 shares of the company. This acquisition, made through the open market on June 22, 2026, represents a minor increase in Ishita Pharmaceuticals' holding from 1.09% to 1.10% of the total share capital. The transaction involved 223 equity shares of Rs. 10 each, with the total equity share capital of Ishita Drugs & Industries Ltd remaining unchanged at Rs. 2,99,03,000/- (29,90,300 shares of Rs. 10 each). This disclosure is made in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ishita Pharmaceuticals, a related party of Ishita Drugs & Industries Ltd, has acquired 55 equity shares of Rs. 10 each in Ishita Drugs & Industries Ltd. This acquisition, made through the open market on June 19, 2026, represents a minor increase in Ishita Pharmaceuticals' shareholding from 1.09% to 1.09% of the total equity. The total equity share capital of Ishita Drugs & Industries Ltd remains Rs. 29,903,000, comprising 2,990,300 shares.

Ishita Drugs & Industries Ltd. announced the approval of its audited financial results for the quarter and year ended March 31, 2026, during a board meeting held on May 30, 2026. The board also approved the Directors’ Report, Corporate Governance report, Management Discussion and Analysis Report, and the notice for the 33rd Annual General Meeting. Additionally, the re-appointment of Internal Auditors for the year 2026-27 was approved, and the Disclosure of Interest of Directors for the same period was taken on record. The auditors issued an unmodified opinion on the financial results.

Ishita Drugs & Industries Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, along with the Directors' Report, Corporate Governance report, Management Discussion and Analysis Report, and notice for the 33rd Annual General Meeting. The board also approved the re-appointment of Internal Auditors for the year 2026-27 and took on record the Disclosure of Interest of Directors.

Ishita Drugs & Industries Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The board will also consider the Directors' Report, Corporate Governance Report, Management Discussion and Analysis Report, and the notice for the 33rd Annual General Meeting. Re-appointment of internal auditors and disclosure of director's interests are also on the agenda. The trading window is closed from April 1, 2026, until 48 hours after the results announcement.

Ishita Drugs & Industries Ltd has announced a Board Meeting scheduled for Saturday, May 30, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The board will also discuss the Directors' Report, Corporate Governance Report, Management Discussion and Analysis Report, and the notice for the 33rd Annual General Meeting. Re-appointment of internal auditors and disclosure of director's interests are also on the agenda. The trading window is closed from April 1, 2026, until 48 hours after the announcement of the audited financial results.

Ishita Drugs & Industries Ltd confirmed that Regulation 32(1) of SEBI (LODR) Regulations, 2015, concerning the Statement of Deviation or Variation from fund proceeds, is not applicable for the financial year ended March 31, 2026. The company did not raise any funds through public issue, rights issue, preferential issue, or QIP during FY26, thus negating the requirement to submit such a statement.

Ishita Drugs & Industries Ltd has announced the closure of the trading window for dealing in securities of the company by designated persons. The closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct. The trading window will remain closed from Wednesday, 01st April, 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and financial year ended 31st March, 2026 to the Stock Exchange.

Ishita Pharmaceuticals, a related party of Ishita Drugs and Industries Limited, has acquired 390 shares of Rs. 10/- each of Ishita Drugs & Industries Ltd. This disclosure was made under regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition was made through the open market on February 26, 2026. The total share capital/voting capital and diluted share/voting capital were taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.